Lupin Limited

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-25 am EDT			5-day change	1st Jan Change
1,595 ^INR	+0.94%		-0.89%	+20.55%

Apr. 24	Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	MT
Apr. 22	INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	RE

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

November 29, 2022 at 01:28 am EST

Lupin Limited (Lupin) announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P. Formoterol Fumarate Inhalation Solution (RLD Perforomist®) had estimated annual sales of USD 268 million in the U.S. (IQVIA MAT September 2022).

Latest news about Lupin Limited

Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	Apr. 23	MT
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	Apr. 22	RE
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection	Apr. 12	MT
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	Apr. 09	MT
Lupin Launches Generic Drug for Inflammatory Lesions of Rosacea in US	Apr. 09	MT
Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States	Apr. 09	CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	Apr. 03	MT
Lupin Names Chief Quality Officer	Apr. 03	MT
Lupin Limited Announces Change in Management	Apr. 03	CI
Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences	Mar. 25	MT
Lupin Limited Receives an Order from the Additional Commissioner of State Tax, Central Division, Patna	Mar. 21	CI
Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms	Mar. 18	MT
Lupin Names Chief Technical Operations Officer	Mar. 18	MT
Lupin Limited Appoints Christoph Funke as Chief Technical Operations Officer	Mar. 18	CI
Boehringer to cut out-of-pocket costs for inhalers to $35	Mar. 07	RE
India pharma companies develop versions of Wegovy to get in on weight-loss windfall	Feb. 22	RE
Lupin Gets US FDA Nod for Minzoya Tablets	Feb. 16	MT
Lupin Limited Receives Approval from U.S. FDA for Minzoyatm	Feb. 16	CI
Lupin Launches Fertility Medicine Ganirelix in US	Feb. 15	MT
Lupin Launches Ganirelix Acetate Injection in the United States	Feb. 15	CI
Lupin Launches Generic Version of Ophthalmic Solution in US	Feb. 13	MT
Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States	Feb. 13	CI
Jefferies Upgrades Lupin to Hold From Underperform, Adjusts Price Target to INR430 From INR520	Feb. 09	MT
Transcript : Lupin Limited, Q3 2024 Earnings Call, Feb 08, 2024	Feb. 08

Chart Lupin Limited

Duration

Period

More charts

Company Profile

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Lupin Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,580 INR

Average target price

1,516 INR

Spread / Average Target

-4.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUPIN LIMITED	+20.55%	8.64B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.46%	358B
MERCK & CO., INC.	+19.28%	322B
ABBVIE INC.	+8.00%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.65%	149B
AMGEN INC.	-6.76%	146B

Other Pharmaceuticals

Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

EPS Revisions